The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
20
01
2024
accepted:
13
06
2024
revised:
08
06
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
19
6
2024
Statut:
epublish
Résumé
With the high incidence of urogenital tumors worldwide, urinary system tumors are among the top 10 most common tumors in men, with prostate cancer ranking first and bladder cancer fourth. Patients with resistant urogenital tumors often have poor prognosis. In recent years, researchers have discovered numerous specific cancer antigens, which has led to the development of several new anti-cancer drugs. Using protein analysis techniques, researchers developed immune checkpoint inhibitors (ICIs) and antibody-conjugated drugs (ADCs) for the treatment of advanced urogenital tumors. However, tumor resistance often leads to the failure of monotherapy. Therefore, clinical trials of the combination of ICIs and ADCs have been carried out in numerous centers around the world. This article reviewed phase 2 and 3 clinical studies of ICIs, ADCs, and their combination in the treatment of urogenital tumors to highlight safe and effective methods for selecting individualized therapeutic strategies for patients. ICIs activate the immune system, whereas ADCs link monoclonal antibodies to toxins, which can achieve a synergistic effect when the two drugs are combined. This synergistic effect provides multiple advantages for the treatment of urogenital tumors.
Identifiants
pubmed: 38898003
doi: 10.1038/s41419-024-06837-w
pii: 10.1038/s41419-024-06837-w
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
433Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82072835
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49.
doi: 10.3322/caac.21820
pubmed: 38230766
Mohanty SK, Lobo A, Cheng L. The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol. 2023;136:123–43.
doi: 10.1016/j.humpath.2022.08.006
pubmed: 36084769
Montironi R, Cimadamore A. Tumors of the urinary system and male genital organs: 2022 World Health Organization Classification and Multidisciplinarity. Eur Urol. 2022;82:483–6.
doi: 10.1016/j.eururo.2022.07.032
pubmed: 35963651
Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20:33–48.
doi: 10.1038/s41571-022-00699-x
pubmed: 36307534
Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs. 2019;35:150923.
doi: 10.1016/j.soncn.2019.08.002
pubmed: 31526550
Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28.
doi: 10.1186/s12943-021-01316-8
pubmed: 33546704
pmcid: 7863491
Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Mol Immunol. 2020;17:807–21.
doi: 10.1038/s41423-020-0488-6
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.
doi: 10.1146/annurev-pathol-042020-042741
pubmed: 33197221
Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186:1652–69.
doi: 10.1016/j.cell.2023.03.006
pubmed: 37059068
Thana M, Wood L. Immune checkpoint inhibitors in genitourinary malignancies. Curr Oncol. 2020;27:S69–S77.
doi: 10.3747/co.27.5121
pubmed: 32368176
pmcid: 7194001
Qi Z, Xu Z, Zhang L, Zou Y, Li J, Yan W, et al. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment. Nat Commun. 2022;13:182.
doi: 10.1038/s41467-021-27833-0
pubmed: 35013322
pmcid: 8748754
Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther. 2020;20:551–61.
doi: 10.1080/14737140.2020.1782201
pubmed: 32552213
pmcid: 7545404
Piombino C, Tonni E, Oltrecolli M, Pirola M, Pipitone S, Baldessari C, et al. Immunotherapy in urothelial cancer: current status and future directions. Expert Rev Anticancer Ther. 2023;23:1141–55.
doi: 10.1080/14737140.2023.2265572
pubmed: 37772970
Uliano J, Nicolò E, Corvaja C, Taurelli Salimbeni B, Trapani D, Curigliano G. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. Expert Rev Clin Pharm. 2022;15:1399–413.
doi: 10.1080/17512433.2022.2142559
Bakhtiar R. Antibody drug conjugates. Biotechnol Lett. 2016;38:1655–64.
doi: 10.1007/s10529-016-2160-x
pubmed: 27334710
D’Angelo A, Chapman R, Sirico M, Sobhani N, Catalano M, Mini E, et al. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. Cancer Chemother Pharm. 2022;90:191–205.
doi: 10.1007/s00280-022-04459-7
Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47:765–79.
doi: 10.1002/eji.201646875
pubmed: 28393361
Pinto BF, Medeiros NI, Teixeira-Carvalho A, Fiuza JA, Eloi-Santos SM, Nunes MCP, et al. Modulation of regulatory T cells activity by distinct CD80 and CD86 interactions with CD28/CTLA-4 in chagas cardiomyopathy. Front Cardiovasc Med. 2022;9:750876.
doi: 10.3389/fcvm.2022.750876
pubmed: 35665256
pmcid: 9162138
Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41:450–65.
doi: 10.1016/j.ccell.2023.02.014
pubmed: 36917950
Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. CA Cancer J Clin. 2021;40:184.
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727–42.
pubmed: 32266087
pmcid: 7136921
Bae J, Accardi F, Hideshima T, Tai YT, Prabhala R, Shambley A, et al. Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022;36:138–54.
doi: 10.1038/s41375-021-01301-6
pubmed: 34290359
Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. Daru. 2020;109:74–103.
Akaiwa M, Dugal-Tessier J, Mendelsohn BA. Antibody-drug conjugate payloads; study of auristatin derivatives. Chem Pharm Bull (Tokyo). 2020;68:201–11.
doi: 10.1248/cpb.c19-00853
pubmed: 32115527
Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, et al. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165–82.
doi: 10.3322/caac.21705
pubmed: 34767258
Arslan FB, Ozturk Atar K, Calis S. Antibody-mediated drug delivery. Int J Pharm. 2021;596:120268.
doi: 10.1016/j.ijpharm.2021.120268
pubmed: 33486037
Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G. Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep. 2022;24:809–17.
doi: 10.1007/s11912-022-01266-4
pubmed: 35305211
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol. 2022;39:2022–vol3.
pubmed: 35819037
Atkins MB, Tannir NM. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. Cancer Treat Rev. 2018;70:127–37.
doi: 10.1016/j.ctrv.2018.07.009
pubmed: 30173085
Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, et al. First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol. 2021;4:755–65.
doi: 10.1016/j.euo.2021.03.001
pubmed: 33757737
Lombardi P, Filetti M, Falcone R, Di Bidino R, Iacovelli R, Ciccarese C, et al. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Cancer Treat Rev. 2022;106:102377.
doi: 10.1016/j.ctrv.2022.102377
pubmed: 35313232
Lai Y, Tang F, Huang Y, He C, Chen C, Zhao J, et al. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy. J Cell Physiol. 2021;236:1616–27.
doi: 10.1002/jcp.29969
pubmed: 32783202
Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, et al. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell. 2021;39:662–77.
doi: 10.1016/j.ccell.2021.03.007
pubmed: 33861994
pmcid: 8268947
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol. 2017;72:962–71.
doi: 10.1016/j.eururo.2017.02.010
pubmed: 28262413
Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126:4156–67.
doi: 10.1002/cncr.33033
pubmed: 32673417
El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021;98:102221.
doi: 10.1016/j.ctrv.2021.102221
pubmed: 34029957
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24:228–38.
doi: 10.1016/S1470-2045(23)00049-9
pubmed: 36858721
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:888–98.
doi: 10.1016/S1470-2045(22)00290-X
pubmed: 35688173
pmcid: 10305087
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.
doi: 10.1056/NEJMoa1816714
pubmed: 30779529
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5:e001079.
doi: 10.1136/esmoopen-2020-001079
pubmed: 33246931
pmcid: 7703447
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388:1767–78.
doi: 10.1056/NEJMoa2212851
pubmed: 37163623
pmcid: 10257898
Borza R, Salgado-Polo F, Moolenaar WH, Perrakis A. Structure and function of the ecto-nucleotide pyrophosphatase/phosphodiesterase (ENPP) family: tidying up diversity. J Biol Chem. 2022;298:101526.
doi: 10.1016/j.jbc.2021.101526
pubmed: 34958798
Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, et al. AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res. 2016;22:1989–99.
doi: 10.1158/1078-0432.CCR-15-1542
pubmed: 26589436
Kollmannsberger C, Choueiri TK, Heng DYC, George S, Jie F, Croitoru R, et al. A randomized phase II study of AGS-16C3F versus axitinib in previously treated patients with metastatic renal cell carcinoma. Oncologist. 2021;26:182–e361.
doi: 10.1002/onco.13628
pubmed: 33289953
pmcid: 7930403
Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–33.
doi: 10.1038/onc.2012.36
pubmed: 22349828
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021;32:746–56.
doi: 10.1016/j.annonc.2021.03.005
pubmed: 33741442
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Narayanan S, Harshman LC, Srinivas S. Second-line therapies in metastatic urothelial carcinoma. Hematol Oncol Clin North Am. 2015;29:341–59.
doi: 10.1016/j.hoc.2014.10.007
pubmed: 25836939
Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol. 2020;32:232–9.
doi: 10.1097/CCO.0000000000000618
pubmed: 32209822
Peng M. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile. Front Immunol. 2022;13:970885.
doi: 10.3389/fimmu.2022.970885
pubmed: 36003383
pmcid: 9394485
Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma. J Urol. 2018;199:1129–42.
doi: 10.1016/j.juro.2017.10.041
pubmed: 29113841
Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018;59:285–96.
doi: 10.4111/icu.2018.59.5.285
pubmed: 30182073
pmcid: 6121021
Powles T, Walker J, Andrew Williams J, Bellmunt J. The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treat Rev. 2020;82:101925.
doi: 10.1016/j.ctrv.2019.101925
pubmed: 31785413
Suzman DL, Agrawal S, Ning YM, Maher VE, Fernandes LL, Karuri S, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. Oncologist. 2019;24:563–9.
doi: 10.1634/theoncologist.2018-0084
pubmed: 30541754
Bellmunt, de Wit J, Fradet R, Climent MA Y, Petrylak DP, Lee JL, et al. Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials. Clin Cancer Res. 2022;28:2050–60.
doi: 10.1158/1078-0432.CCR-21-3089
pubmed: 35247908
Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92.
doi: 10.1016/S1470-2045(17)30616-2
pubmed: 28967485
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22:919–30.
doi: 10.1016/S1470-2045(21)00147-9
pubmed: 34051177
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:931–45.
doi: 10.1016/S1470-2045(21)00152-2
pubmed: 34051178
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, et al. BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer. J Clin Invest. 2022;132:e145666.
doi: 10.1172/JCI145666
pubmed: 35503263
pmcid: 9197524
Bellone M, Elia AR. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. Cytokine Growth Factor Rev. 2017;36:17–24.
doi: 10.1016/j.cytogfr.2017.06.002
pubmed: 28606732
Sheng X, Chen H, Hu B, Yao X, Liu Z, Yao X, et al. Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03. Clin Cancer Res. 2022;28:489–97.
doi: 10.1158/1078-0432.CCR-21-2210
pubmed: 34740921
Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, et al. Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy. Clin Cancer Res. 2020;26:61–70.
doi: 10.1158/1078-0432.CCR-19-1635
pubmed: 31801732
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22.
doi: 10.1016/S1470-2045(17)30065-7
pubmed: 28131785
Rajasekaran N, Wang X, Ravindranathan S, Chin DJ, Tseng SY, Klakamp SL, et al. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells. Cancer Immunol Immunother. 2024;73:60.
doi: 10.1007/s00262-024-03635-3
pubmed: 38400933
pmcid: 10894093
Zhang L, Hao B, Geng Z, Geng Q. Toripalimab: the first domestic anti-tumor PD-1 antibody in china. Front Immunol. 2021;12:730666.
doi: 10.3389/fimmu.2021.730666
pubmed: 35095833
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.
doi: 10.3389/fimmu.2022.964442
pubmed: 36177034
pmcid: 9513184
Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, et al. Phase 2 trial of atezolizumab in bacillus calmette-guérin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605. Eur Urol. 2023;84:536–44.
doi: 10.1016/j.eururo.2023.08.004
pubmed: 37596191
Sotelo M, Alonso-Gordoa T, Gajate P, Gallardo E, Morales-Barrera R, Pérez-Gracia JL, et al. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Transl Oncol. 2021;23:882–91.
doi: 10.1007/s12094-020-02482-9
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017;389:67–76.
doi: 10.1016/S0140-6736(16)32455-2
pubmed: 27939400
Funt SA, Lattanzi M, Whiting K, Al-Ahmadie H, Quinlan C, Teo MY, et al. Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial. J Clin Oncol. 2022;40:1312–22.
doi: 10.1200/JCO.21.01485
pubmed: 35089812
pmcid: 9797229
Inman BA, Hahn NM, Stratton K, Kopp R, Sankin A, Skinner E, et al. A phase 1b/2 study of atezolizumab with or without bacille calmette-guérin in patients with high-risk non-muscle-invasive bladder cancer. Eur Urol Oncol. 2023;6:313–20.
doi: 10.1016/j.euo.2023.01.013
pubmed: 36803840
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58–67.
doi: 10.1182/blood-2017-06-741033
pubmed: 29118008
Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33–59.
doi: 10.1007/978-981-15-3266-5_3
pubmed: 32185706
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1574–88.
doi: 10.1016/S1470-2045(20)30541-6
pubmed: 32971005
Vranić S, Bešlija S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci. 2021;21:1–4.
pubmed: 32530388
pmcid: 7861626
Nini A, Hoffmann MJ, Lampignano R, Große Siemer R, van Dalum G, Szarvas T, et al. Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. Cytom B Clin Cytom. 2020;98:355–67.
doi: 10.1002/cyto.b.21877
Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47:87–94.
doi: 10.1007/s11255-014-0866-z
pubmed: 25384433
Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24:913–25.
doi: 10.1007/s10120-021-01168-7
pubmed: 33945049
pmcid: 8205919
Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res. 2021;27:43–51.
doi: 10.1158/1078-0432.CCR-20-2488
pubmed: 33109737
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28.
doi: 10.1056/NEJMoa1814017
de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Cancer Med. 2023;12:12071–83.
doi: 10.1002/cam4.5893
pubmed: 37119523
pmcid: 10278525
Avellini C, Licini C, Lazzarini R, Gesuita R, Guerra E, Tossetta G, et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget. 2017;8:58642–53.
doi: 10.18632/oncotarget.17407
pubmed: 28938585
pmcid: 5601681
Alhalabi O, Altameemi L, Campbell MT, Meric-Bernstam F. Recent advances in the development of antibody-drug conjugates in urothelial cancer. Cancer J. 2022;28:417–22.
doi: 10.1097/PPO.0000000000000632
pubmed: 36383903
Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, et al. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75–9.
doi: 10.1016/j.clgc.2015.10.002
pubmed: 26541586
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474–85.
doi: 10.1200/JCO.20.03489
pubmed: 33929895
pmcid: 8315301
Huang L, Yang Y, Yang F, Liu S, Zhu Z, Lei Z, et al. Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med. 2018;42:1771–85.
pubmed: 30015855
pmcid: 6108866
Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: a critical review. Biochim Biophys Acta Rev Cancer. 2020;1874:188436.
doi: 10.1016/j.bbcan.2020.188436
pubmed: 32976980
Eyvazi S, Farajnia S, Dastmalchi S, Kanipour F, Zarredar H, Bandehpour M. Antibody based EpCAM targeted therapy of cancer, review and update. Curr Cancer Drug Targets. 2018;18:857–68.
doi: 10.2174/1568009618666180102102311
pubmed: 29295696
Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. 2012;188:1712–8.
doi: 10.1016/j.juro.2012.07.020
pubmed: 22998907
Powles T, Rosenberg JE, Sonpavde GP, Loriot Y, Durán I, Lee JL, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med. 2021;384:1125–35.
doi: 10.1056/NEJMoa2035807
pubmed: 33577729
pmcid: 8450892
Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin Biol Ther. 2021;21:863–73.
doi: 10.1080/14712598.2021.1929168
pubmed: 34030536
pmcid: 8224177
Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:872–82.
doi: 10.1016/S1470-2045(21)00094-2
pubmed: 33991512
Yu J, Wu S, Li R, Jiang Y, Zheng J, Li Z, et al. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium. Haematologica. 2023;16:85.
Melekos MD, Moutzouris GD. Intravesical therapy of superficial bladder cancer. Curr Pharm Des. 2000;6:345–59.
doi: 10.2174/1381612003401019
pubmed: 10637383
Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of resistance to antibody-drug conjugates. Cancers (Basel). 2023;15:1278.
doi: 10.3390/cancers15041278
pubmed: 36831621
Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713.
doi: 10.3390/cancers15030713
pubmed: 36765668
Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Expert Opin Investig Drugs. 2018;36:121–35.
O’Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, et al. Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. J Clin Oncol. 2023;41:4107–17.
doi: 10.1200/JCO.22.02887
pubmed: 37369081
pmcid: 10852367
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023;41:22–31.
doi: 10.1200/JCO.22.01643
pubmed: 36041086
Wasim S, Lee SY, Kim J. Complexities of prostate cancer. Int J Mol Sci. 2022;23:14257.
doi: 10.3390/ijms232214257
pubmed: 36430730
pmcid: 9696501
Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.
doi: 10.3390/molecules27175730
pubmed: 36080493
pmcid: 9457814
Mollica V, Di Nunno V, Cimadamore A, Lopez-Beltran A, Cheng L, Santoni M, et al. Molecular mechanisms related to hormone inhibition resistance in prostate cancer. Cells. 2019;8:43.
doi: 10.3390/cells8010043
pubmed: 30642011
pmcid: 6356740
Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. Annu Rev Med. 2019;70:479–99.
doi: 10.1146/annurev-med-051517-011947
pubmed: 30691365
pmcid: 6441973
Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020;6:702–15.
doi: 10.1016/j.trecan.2020.04.010
pubmed: 32534790
Runcie KD, Dallos MC. Prostate cancer immunotherapy-finally in from the cold? Curr Oncol Rep. 2021;23:88.
doi: 10.1007/s11912-021-01084-0
pubmed: 34125308
Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, et al. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther. 2021;9:1958–69.
doi: 10.1016/j.ymthe.2021.04.029
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395–405.
doi: 10.1200/JCO.19.01638
pubmed: 31774688
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–12.
doi: 10.1016/S1470-2045(14)70189-5
pubmed: 24831977
pmcid: 4418935
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–7.
doi: 10.1200/JCO.2016.69.1584
pubmed: 28034081
Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82:22–30.
doi: 10.1016/j.eururo.2022.02.023
pubmed: 35397952
Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, et al. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. J Immunother Cancer. 2020;8:e000642.
doi: 10.1136/jitc-2020-000642
pubmed: 32616555
pmcid: 7333874
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.
doi: 10.1056/NEJMoa1506859
pubmed: 26510020
pmcid: 5228595
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J Clin Oncol. 2023;41:3839–50.
doi: 10.1200/JCO.23.00233
pubmed: 37290035
pmcid: 10419579
Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, et al. Pembrolizumab plus olaparib in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b/2 KEYNOTE-365 cohort a study. Eur Urol. 2023;83:15–26.
doi: 10.1016/j.eururo.2022.08.005
pubmed: 36055895
Sharma P, Pachynski RK, Narayan V, Fléchon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell. 2020;38:489–99.
doi: 10.1016/j.ccell.2020.08.007
pubmed: 32916128
McNeel DG, Eickhoff JC, Wargowski E, Johnson LE, Kyriakopoulos CE, Emamekhoo H, et al. Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2022;10:e004198.
doi: 10.1136/jitc-2021-004198
pubmed: 35277461
pmcid: 8919462
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50:472–83.
doi: 10.1111/j.1365-2559.2007.02635.x
pubmed: 17448023
Van de Wiele C, Sathekge M, de Spiegeleer B, De Jonghe PJ, Debruyne PR, Borms M, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919–27.
pubmed: 32282924
Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26:2147–54.
doi: 10.1200/JCO.2007.15.0532
pubmed: 18362364
Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, et al. Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016;34:530.
doi: 10.1016/j.urolonc.2016.07.005
pmcid: 5464417
Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020;80:99–108.
doi: 10.1002/pros.23922
pubmed: 31742767
Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4:1344–51.
doi: 10.1001/jamaoncol.2018.2168
pubmed: 29978216
pmcid: 6233779
Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16:1767–73.
doi: 10.7150/ijbs.41105
pubmed: 32398947
pmcid: 7211166
Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15:eadf6724.
doi: 10.1126/scitranslmed.adf6724
pubmed: 37163614
pmcid: 10574140
Shenderov E, De Marzo AM, Lotan TL, Wang H, Chan S, Lim SJ, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nat Med. 2023;29:888–97.
doi: 10.1038/s41591-023-02284-w
pubmed: 37012549
pmcid: 10921422
Xu M, Evans L, Bizzaro CL, Quaglia F, Verrillo CE, Li L, et al. STEAP1-4 (six-transmembrane epithelial antigen of the prostate 1-4) and their clinical implications for prostate cancer. Cancers (Basel). 2022;14:4034.
doi: 10.3390/cancers14164034
pubmed: 36011027
Zhao C, Xiong K, Ji Z, Liu F, Li X. The prognostic value and immunological role of STEAP1 in pan-cancer: a result of data-based analysis. Oxid Med Cell Longev. 2022;2022:8297011.
pubmed: 35313641
pmcid: 8933652
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, et al. Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. J Nucl Med. 2019;60:1517–23.
doi: 10.2967/jnumed.118.222844
pubmed: 31053681
pmcid: 6836860
Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost. 2019;45:385–95.
doi: 10.1055/s-0039-1687894
pubmed: 31096306
pmcid: 6546519
de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:383–93.
doi: 10.1016/S1470-2045(18)30859-3
pubmed: 30745090
Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, et al. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021;5:74.
doi: 10.1038/s41698-021-00214-y
pubmed: 34354225
pmcid: 8342450
Kanesvaran R, Castro E, Wong A, Fizazi K, Chua MLK, Zhu Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open. 2022;7:100518.
doi: 10.1016/j.esmoop.2022.100518
pubmed: 35797737
pmcid: 9434138
Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, et al. Phase II trial of pembrolizumab and anti-CD3 x anti-HER2 bispecific antibody-armed activated T cells in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023;29:122–33.
doi: 10.1158/1078-0432.CCR-22-1601
pubmed: 36255393
pmcid: 9812860
Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, et al. ADXS31142 immunotherapy ± pembrolizumab treatment for metastatic castration-resistant prostate cancer: open-label phase I/II KEYNOTE-046 study. Oncologist. 2022;27:453–61.
doi: 10.1093/oncolo/oyac048
pubmed: 35373299
pmcid: 9177110
Aldrink JH, Glick RD, Baertschiger RM, Kulaylat AN, Lautz TB, Christison-Lagay E, et al. Update on pediatric testicular germ cell tumors. J Pediatr Surg. 2022;57:690–9.
doi: 10.1016/j.jpedsurg.2021.04.001
pubmed: 33975708
Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32:3085–92.
doi: 10.1200/JCO.2014.56.0896
pubmed: 25024068
Tuzel E, Yorukoglu K, Ozkara E, Kirkali Z. Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors. Cent Eur J Urol. 2015;68:45–50.
doi: 10.5173/ceju.2015.01.486
Adra N, Einhorn LH. Salvage therapy for relapsed testicular cancer. Oncotarget. 2017;8:69200–1.
doi: 10.18632/oncotarget.20573
pubmed: 29050196
pmcid: 5642471
Savelyeva AV, Medvedev KE. Seminoma subtypes differ in the organization and functional state of the immune microenvironment. 3 Biotech. 2023;13:110.
doi: 10.1007/s13205-023-03530-1
pubmed: 36875959
pmcid: 9981831
Chieffi P, De Martino M, Esposito F. Further insights into testicular germ cell tumor oncogenesis: potential therapeutic targets. Expert Rev Anticancer Ther. 2020;20:189–95.
doi: 10.1080/14737140.2020.1736566
pubmed: 32164473
Qu N, Ogawa Y, Kuramasu M, Nagahori K, Sakabe K, Itoh M. Immunological microenvironment in the testis. Reprod Med Biol. 2020;19:24–31.
doi: 10.1002/rmb2.12293
pubmed: 31956282
Fankhauser CD, Curioni-Fontecedro A, Allmann V, Beyer J, Tischler V, Sulser T, et al. Frequent PD-L1 expression in testicular germ cell tumors. Br J Cancer. 2015;113:411–3.
doi: 10.1038/bjc.2015.244
pubmed: 26171934
pmcid: 4522642
Cierna Z, Mego M, Miskovska V, Machalekova K, Chovanec M, Svetlovska D, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016;27:300–5.
doi: 10.1093/annonc/mdv574
pubmed: 26598537
Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany C, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018;29:209–14.
doi: 10.1093/annonc/mdx680
pubmed: 29045540
Tsimberidou AM, Vo HH, Subbiah V, Janku F, Piha-Paul S, Yilmaz B, et al. Pembrolizumab in patients with advanced metastatic germ cell tumors. Oncologist. 2021;26:558–e1098.
doi: 10.1002/onco.13682
pubmed: 33491277
pmcid: 8265349
Zschäbitz S, Lasitschka F, Hadaschik B, Hofheinz RD, Jentsch-Ullrich K, Grüner M, et al. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. Eur J Cancer B Oral Oncol. 2017;76:1–7.
doi: 10.1016/j.ejca.2017.01.033
Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, et al. Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. Int J Urol. 2022;29:741–7.
doi: 10.1111/iju.14885
pubmed: 35462438
pmcid: 9545636
Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133:446–50.
pubmed: 2849300
pmcid: 1880812
Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–65.
doi: 10.1182/blood-2003-01-0039
pubmed: 12714494
Shea L, Mehta-Shah N. Brentuximab vedotin in the treatment of peripheral T cell lymphoma and cutaneous T cell lymphoma. Curr Hematol Malig Rep. 2020;15:9–19.
doi: 10.1007/s11899-020-00561-w
pubmed: 32016790
Albany C, Einhorn L, Garbo L, Boyd T, Josephson N, Feldman DR. Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases. Oncologist. 2018;23:316–23.
doi: 10.1634/theoncologist.2017-0544
pubmed: 29222199
Ashkar R, Feldman DR, Adra N, Zaid MA, Funt SA, Althouse SK, et al. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors. Expert Opin Investig Drugs. 2021;39:1656–63.
Deng S, Xuan Z, Feng J, Li H, Wang B, Yang Z, et al. Global research trends in penile cancer: Bibliometric and visualized analysis. Front Oncol. 2022;12:1091816.
doi: 10.3389/fonc.2022.1091816
pubmed: 36686820
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
doi: 10.3322/caac.21590
pubmed: 31912902
Martz N, Bodokh Y, Gautier M, Thamphya B, Schiappa R, Lam Cham Kee D, et al. High-dose rate brachytherapy in localized penile cancer: 5-Year clinical outcome analysis. Clin Transl Radiat Oncol. 2021;27:89–95.
pubmed: 33537466
pmcid: 7841215
Chadha J, Chahoud J, Spiess PE. An update on treatment of penile cancer. Ther Adv Med Oncol. 2022;14:17588359221127254.
doi: 10.1177/17588359221127254
pubmed: 36172172
pmcid: 9511530
Baweja A, Mar N. Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. J Oncol Pharm Pr. 2021;27:212–5.
doi: 10.1177/1078155220922602
Keller BA, Pastukhova E, Lo B, Sekhon HS, Flood TA. Molecular pathogenesis of penile squamous cell carcinoma: current understanding and potential treatment implications. Arch Pathol Lab Med. 2023;147:722–34.
doi: 10.5858/arpa.2021-0592-RA
pubmed: 36136297
Ribera-Cortada I, Guerrero-Pineda J, Trias I, Veloza L, Garcia A, Marimon L, et al. Pathogenesis of penile squamous cell carcinoma: molecular update and systematic review. Int J Mol Sci. 2021;23:251.
doi: 10.3390/ijms23010251
pubmed: 35008677
pmcid: 8745288
Gupta S, Sonpavde G. Emerging systemic therapies for the management of penile cancer. Urol Clin North Am. 2016;43:481–91.
doi: 10.1016/j.ucl.2016.06.009
pubmed: 27717434
Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21:47.
doi: 10.1186/s12943-022-01530-y
pubmed: 35151318
pmcid: 8840702
Yahya EB, Alqadhi AM. Recent trends in cancer therapy: a review on the current state of gene delivery. Life Sci. 2021;269:119087.
doi: 10.1016/j.lfs.2021.119087
pubmed: 33476633
Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175–96.
doi: 10.1038/s41573-018-0006-z
pubmed: 30622344
pmcid: 6410566
Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87.
doi: 10.1038/nrc.2016.36
pubmed: 27079802
pmcid: 5381938
Li B, Chan HL, Chen P. Immune checkpoint inhibitors: basics and challenges. Curr Med Chem. 2019;26:3009–25.
doi: 10.2174/0929867324666170804143706
pubmed: 28782469
Ding P, Wen L, Tong F, Zhang R, Huang Y, Dong X. Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer. Cancer Drug Resist. 2022;5:147–64.
pubmed: 35582541
pmcid: 8992596
Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669–80.
doi: 10.1038/s41568-021-00378-6
pubmed: 34272515
McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17:339–51.
doi: 10.1208/s12248-014-9710-8
pubmed: 25604608
pmcid: 4365093
Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.
doi: 10.1038/s41392-022-00947-7
pubmed: 35318309
pmcid: 8941077
Fuentes-Antrás J, Genta S, Vijenthira A, Siu LL. Antibody-drug conjugates: in search of partners of choice. Trends Cancer. 2023;9:339–54.
doi: 10.1016/j.trecan.2023.01.003
pubmed: 36746689
Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst Monogr. 2019;111:538–49.
doi: 10.1093/jnci/djz035
Seligson JM, Patron AM, Berger MJ, Harvey RD, Seligson ND. Sacituzumab govitecan-hziy: an antibody-drug conjugate for the treatment of refractory, metastatic, triple-negative breast cancer. Ann Pharmacother. 2021;55:921–31.
doi: 10.1177/1060028020966548
pubmed: 33070624
Aykut B, Lidsky ME. Colorectal cancer liver metastases: multimodal therapy. Surg Oncol Clin N Am. 2023;32:119–41.
doi: 10.1016/j.soc.2022.07.009
pubmed: 36410912
Zhang JH, Starr SL, Chamie K. Contemporary systemic therapies in urothelial carcinoma. Urology. 2023;174:150–8.
doi: 10.1016/j.urology.2023.01.007
pubmed: 36682700
Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A. The evolving landscape of antibody-drug conjugates for urothelial carcinoma. Clin Genitourin Cancer. 2021;19:183–93.
doi: 10.1016/j.clgc.2020.11.006
pubmed: 33558159
Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1195–204.
doi: 10.1001/jamaoncol.2019.1549
pubmed: 31318407
pmcid: 6646995